Pfizer (NYSE:PFE) Sets New 12-Month Low at $25.20

Pfizer Inc. (NYSE:PFE) shares reached a new 52-week low during trading on Friday . The company traded as low as $25.20 and last traded at $25.45, with a volume of 5205277 shares trading hands. The stock had previously closed at $25.26.

Analysts Set New Price Targets

PFE has been the topic of a number of analyst reports. Argus cut Pfizer from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Guggenheim assumed coverage on Pfizer in a research note on Friday, February 23rd. They set a “buy” rating and a $36.00 target price on the stock. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price target for the company. in a report on Thursday, January 4th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a report on Monday, April 15th. Eleven equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $36.33.

Pfizer Stock Performance

The business has a fifty day simple moving average of $26.96 and a two-hundred day simple moving average of $28.39. The company has a debt-to-equity ratio of 0.69, a current ratio of 0.91 and a quick ratio of 0.69. The company has a market cap of $143.83 billion, a PE ratio of 70.56, a price-to-earnings-growth ratio of 1.14 and a beta of 0.61.

Pfizer (NYSE:PFE) last posted its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.29. The company had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. Pfizer’s revenue was down 41.3% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.14 earnings per share. Research analysts anticipate that Pfizer Inc. will post 2.24 earnings per share for the current year.

Pfizer Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 14th. Shareholders of record on Friday, May 10th will be issued a dividend of $0.42 per share. The ex-dividend date is Thursday, May 9th. This represents a $1.68 dividend on an annualized basis and a yield of 6.61%. Pfizer’s dividend payout ratio is currently 466.67%.

Institutional Trading of Pfizer

Several hedge funds and other institutional investors have recently made changes to their positions in PFE. Briaud Financial Planning Inc purchased a new stake in shares of Pfizer during the 3rd quarter valued at $30,000. GoalVest Advisory LLC increased its position in shares of Pfizer by 304.9% in the 4th quarter. GoalVest Advisory LLC now owns 1,077 shares of the biopharmaceutical company’s stock valued at $31,000 after acquiring an additional 811 shares during the period. Creekmur Asset Management LLC acquired a new position in shares of Pfizer in the 4th quarter valued at $32,000. Trivant Custom Portfolio Group LLC increased its position in shares of Pfizer by 100.0% in the 1st quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after acquiring an additional 600 shares during the period. Finally, Mizuho Securities Co. Ltd. acquired a new position in shares of Pfizer in the 3rd quarter valued at $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.